 |
|
|
| |
SWIFT Study: Switching From Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF)
|
| |
| |
Reported by Jules Levin
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention
July 17-20, 2011, Rome, Italy
R Campo1, E DeJesus2, H Khanlou3, H Wang4, K White4,
L Dau4, J Flaherty4, and T Fralich4
1Univ of Miami Sch of Med, Miami, FL, USA;
2Orlando Immunology Ctr, Orlando, FL, USA;
3AIDS Healthcare Foundation, Los Angeles, CA, USA;
4Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
